Is the US prepared to deal with another pandemic or widespread health crisis?
The US is better prepared in several technical and material areas than it was before COVID-19, but significant gaps remain in coordination, sustained funding, workforce, public trust, local capacity, and political consistency, leaving it not fully ready for another severe pandemic or widespread health crisis. Assessments from bipartisan commissions, government watchdogs, the WHO, CDC, and others consistently describe progress mixed with persistent vulnerabilities.[1][2]
Key Improvements Post-COVID
The Biden-Harris administration (and ongoing efforts) invested heavily in rebuilding after COVID-19 exposed major shortfalls:
These steps have enabled quicker responses to threats like H5N1 (stockpiling vaccines, monitoring), mpox, Marburg/Ebola support abroad, and routine respiratory seasons.
Persistent Gaps and Vulnerabilities
Experts emphasize that preparedness is incomplete and fragile:
Bottom Line
The US has stronger stockpiles, better data/surveillance tools, advanced R&D platforms, and institutional learning than pre-2020, enabling faster initial responses to known or similar threats. It is not starting from the same low base. However, it is not fully prepared for a high-severity, novel, or rapidly escalating crisis due to coordination fragmentation, uneven local readiness, workforce/trust issues, funding volatility, and incomplete implementation of lessons. A moderate flu-like event might be managed better; a COVID-scale or worse event (higher lethality, more disruptive) would still strain systems heavily.[9]
Preparedness is ongoing, not a destination—it requires consistent bipartisan investment, leadership, exercises, and addressing root issues like healthcare capacity and social determinants. Ongoing threats (avian flu, other zoonoses, antimicrobial resistance, potential bioweapons) underscore the urgency. Independent reviews (Commission, GAO, JEE) provide clear roadmaps; execution and sustained political will determine outcomes.
Citations (15)
- https://biodefensecommission.org/reports/the-national-blueprint-for-biodefense/
Backs: “Assessments from bipartisan commissions, government watchdogs, the WHO, CDC, and others consistently describe progress mixed with persistent vulnerabilities.”
attribution, article, points to no. Claim: Bipartisan commissions describe progress mixed with persistent vulnerabilities; the nation remains dangerously vulnerable to biological threats.
- https://bidenwhitehouse.archives.gov/briefing-room/statements-releases/2025/01/14/report-the-biden-harris-administration-roadmap-for-pandemic-preparedness-and-response/
Backs: “Assessments from bipartisan commissions, government watchdogs, the WHO, CDC, and others consistently describe progress mixed with persistent vulnerabilities.”
evidence, official document, points to yes. Claim: Administration report on post-COVID gains: expanded stockpile, surveillance, coordination structures, and the White House pandemic office.
- https://aspr.hhs.gov/SNS/Pages/Stockpile-Responses.aspx
Backs: “Sustainment includes quality checks, shelf-life extensions, and efforts to push stockpiles closer to state/local levels.”
evidence, data page, points to yes. Claim: The Strategic National Stockpile has supported responses to H5N1, mpox, and other outbreaks by deploying PPE, antivirals, and vaccines.
- https://www.aspr.gov/news-updates/blog/2025-12/stand-ready-move-fast-save-lives
Backs: “Sustainment includes quality checks, shelf-life extensions, and efforts to push stockpiles closer to state/local levels.”
evidence, article, points to yes. Claim: Stockpile sustainment includes quality checks, shelf-life extensions, and moving supplies closer to state and local levels.
- https://www.cdc.gov/washington/testimony/2024/t20241114.htm
Backs: ““Warm base” partnerships with clinical labs aim for faster test development and surge capacity.”
statistic, official document, points to yes. Claim: Electronic case reporting grew from under 200 facilities to over 45,000; CDC reforms and surge workforce improve readiness.
- https://www.niaid.nih.gov/news-events/nih-awards-establish-pandemic-preparedness-research-network
Backs: “Investments in domestic manufacturing aim to reduce supply-chain risks.”
evidence, article, points to yes. Claim: NIH's ReVAMPP network funds research on high-priority pathogen families for vaccines and monoclonal antibodies.
- https://www.who.int/publications/i/item/9789240105409
Backs: “It scored highly in areas like labs, surveillance foundations, and some emergency management, reflecting investments.”
evidence, official document, neutral. Claim: WHO evaluation found strong US capacities but recommended strengthening local roots, workforce, funding, trust, and equity.
- https://biodefensecommission.org/wp-content/uploads/2024/05/National-Blueprint-for-Biodefense-2024_final_.pdf
Backs: “Biological threats (natural, accidental, deliberate) are growing.”
evidence, official document, points to no. Claim: The Blueprint issued 36 recommendations and 185 action items, noting fragmented efforts across 15+ agencies.
- https://www.stimson.org/2024/prepare-for-the-next-biothreat-now/
Backs: “Funding and milestones often lack clear ties to risk reduction.”
evidence, article, points to no. Claim: A COVID-scale or worse event would still strain systems heavily; GAO recommendations remain unimplemented.
- https://www.gao.gov/products/gao-25-107588
Backs: “Funding and milestones often lack clear ties to risk reduction.”
evidence, official document, points to no. Claim: GAO identifies ongoing issues in HHS emergency leadership and coordination.
- https://www.gao.gov/products/gao-25-106980
Backs: “Funding and milestones often lack clear ties to risk reduction.”
evidence, official document, points to no. Claim: GAO finds ongoing gaps in diagnostic testing strategy, program coordination, and data systems.
- https://manhattan.institute/article/are-us-health-agencies-prepared-for-the-next-pandemic
Backs: “Global contributions (Pandemic Fund, CEPI) have seen pledges but face congressional and administrative hurdles.”
evidence, article, points to no. Claim: Stockpile and programs face funding shortfalls, PAHPA reauthorization problems, and waning supplemental funds.
- https://www.kff.org/public-opinion/kff-health-tracking-poll-ebola-pandemic-preparedness/
Backs: “Supply chains, hospital surge capacity, and novel pathogen “Pathogen X” readiness still have risks.”
statistic, data page, points to no. Claim: Public opinion is divided, with a plurality in some polls viewing the US as less prepared than in 2020.
- https://www.notus.org/health-science/white-house-pandemic-preparedness
Backs: “Supply chains, hospital surge capacity, and novel pathogen “Pathogen X” readiness still have risks.”
evidence, article, points to no. Claim: The White House pandemic office's staffing fluctuated significantly after the 2025 transition.
- https://www.bloomberg.com/news/articles/2026-06-11/is-the-us-prepared-for-the-next-pandemic-how-trump-s-policies-weakened-defenses
Backs: “Supply chains, hospital surge capacity, and novel pathogen “Pathogen X” readiness still have risks.”
evidence, article, points to no. Claim: Policy changes and cuts to public health and global health security have raised expert alarms about weakened defenses.